Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report
In this study, we reported a case of EBV-HLH successfully treated with programmed cell death protein-1 (PD-1) inhibitor in combination with rituximab. The regimen had a good curative effect, and we successfully detected the trend of early recurrence. Our findings indicated that PD-1 inhibitor in combination with rituximab may help to treat EBV-HLH and maintain EBV-infected T and B whole-line lymphocytes.PMID:37873944 | DOI:10.22034/iji.2023.99254.2629 (Source: Iranian Journal of Immunology)
Source: Iranian Journal of Immunology - October 24, 2023 Category: Allergy & Immunology Authors: Miao Zhu Jun Zhang Qingqing Shi Xing Sun Haibo Wang Mei Sun Yanqing Liu Source Type: research
